Refractory, primary Central Nervous System Neoplasm Active Not Recruiting Phase 2 Trials for Selumetinib (DB11689)

Also known as: Refractory Primary Central Nervous System Neoplasm

DBCOND0142769 (Refractory, primary Central Nervous System Neoplasm)Active Not Recruiting2 IdentifierTitlePurposeDrugs
NCT03213691Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Treatment